Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Ascend Wellness Holdings, Inc.Ascend Wellness Holdings Reports $84.99 Million Net Loss Despite 8% Revenue Growth in 2024
ACTUATE THERAPEUTICS, INC.Actuate Therapeutics Reports $27.3 Million Net Loss for 2024, IPO Raises $22 Million
Candel Therapeutics, Inc.Candel Therapeutics Reports $55.2 Million Net Loss for 2024, Highlights Positive Clinical Trial Data
Enliven Therapeutics, Inc.Enliven Therapeutics Reports $89M Net Loss for 2024, Increases R&D Spending
Lyra Therapeutics, Inc.Lyra Therapeutics Reports $93.4 Million Net Loss for 2024 Amid Restructuring and Trial Setbacks
IN8BIO, INC.IN8bio Reports $30.4 Million Net Loss for 2024, Cash Position Declines to $11.1 Million
Logan Ridge Finance Corp.Logan Ridge Finance Corporation Reports 3.7% Increase in Total Investment Income for 2024
Vacasa, Inc.Vacasa Reports $154.9 Million Net Loss in 2024, Revenue Decreases by 19%
MACH NATURAL RESOURCES LPMach Natural Resources LP Reports 27% Revenue Increase to $969.6 Million for 2024
Allogene Therapeutics, Inc.Allogene Therapeutics Reports $257.59 Million Net Loss for 2024, Revenue Drops 77%
Rallybio CorpRallybio Corp. Reports $57.8 Million Net Loss for 2024, Improved from Previous Year
Gossamer Bio, Inc.Gossamer Bio Reports $56.5 Million Net Loss for 2024, Revenue Driven by Collaboration with Chiesi
Ocugen, Inc.Ocugen Reports $54.05 Million Net Loss for 2024, Revenue Declines to $4.06 Million
First Northwest BancorpFirst Northwest Bancorp Reports $6.6 Million Net Loss for 2024
Xilio Therapeutics, Inc.Xilio Therapeutics Reports $58.2 Million Net Loss for 2024, Improved from Previous Year
Wheels Up Experience Inc.Wheels Up Experience Inc. Reports $339.6M Net Loss for Fiscal Year 2024, Revenue Declines 36.8%
Mallinckrodt plcMallinckrodt Reports $1.98 Billion in Net Sales for Fiscal Year 2024, Driven by Specialty Generics Growth
Bioventus Inc.Bioventus Reports $573.3 Million in Net Sales for Fiscal Year 2024, Significant Loss Reduction
Rapport Therapeutics, Inc.Rapport Therapeutics Reports $78.3 Million Net Loss for 2024, Increases R&D Spending
TScan Therapeutics, Inc.TScan Therapeutics Reports $127.5 Million Net Loss for 2024, Revenue Drops to $2.8 Million
Q32 Bio Inc.Q32 Bio Inc. Reports $47.7 Million Net Loss for 2024, Completes Merger with Homology Medicines
Werewolf Therapeutics, Inc.Werewolf Therapeutics Reports $70.5 Million Net Loss and $1.9 Million Revenue for Fiscal Year 2024
SOUNDHOUND AI, INC.SoundHound AI Reports 85% Revenue Growth to $84.7 Million in 2024
Amerant Bancorp Inc.Amerant Bancorp Reports $15.7 Million Net Loss for 2024, Total Assets Increase to $9.9 Billion
Seres Therapeutics, Inc.Seres Therapeutics Reports $125.7M Net Loss for 2024, Sells VOWST Business for $234.2M